| Pure Foods Tasmania Limited (PFT) ORDINARY FULLY PAID |
Consumer Staple |
$8 |
Easter trading update and ranging with Costco
|
26 Feb 2026 10:00AM |
$0.029 |
$0.026 |
fallen by
10.34%
|
|
PFT - Price-sensitive ASX Announcement
Full Release
Key Points
- Easter orders for Tasmanian Pâté increased 71% year-on-year.
- Approximately $150,000 additional revenue from Easter period.
- New product ranging secured with Costco Australia.
- Initial Costco products include 300g Pâté SKU and 1kg Daly Potato bags.
- Products scheduled to be on shelves from March 16, 2026.
- Initial eight-week Costco program expected to generate $150,000 in revenue.
- Combined revenue growth from Easter and Costco expected to be $300,000.
- Opportunity to expand range and shelf presence subject to performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alexium International Group Limited (AJX) ORDINARY FULLY PAID |
Materials |
$23 |
Half Year Report and Accounts
|
26 Feb 2026 10:00AM |
$0.007 |
$0.008 |
risen by
7.14%
|
|
AJX - Price-sensitive ASX Announcement
Full Release
Key Points
- Alexium International Group Limited focused on strategic initiatives.
- The company worked on enhancing product offerings and expanding market reach.
- Financial statements include profit and loss, balance sheets, and cash flow statements.
- Emphasis on research and development and market expansion activities.
- Efforts were made to optimize operations amid challenging market conditions.
- The aim was to strengthen the position in the specialty chemicals sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Notification of cessation of securities - ACR
|
26 Feb 2026 9:59AM |
$0.014 |
$0.011 |
fallen by
21.43%
|
|
| QBE Insurance Group Limited (QBE) ORDINARY FULLY PAID |
Financials |
$33,825 |
Application for quotation of securities - QBE
|
26 Feb 2026 9:59AM |
$21.890 |
$22.640 |
risen by
3.43%
|
|
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$9 |
Proposed issue of securities - NVO
|
26 Feb 2026 9:59AM |
$0.130 |
$0.080 |
fallen by
38.46%
|
|
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$9 |
Proposed issue of securities - NVO
|
26 Feb 2026 9:58AM |
$0.130 |
$0.080 |
fallen by
38.46%
|
|
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$99 |
Dividend/Distribution - CAM
|
26 Feb 2026 9:58AM |
$0.700 |
$0.695 |
fallen by
0.71%
|
|
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$9 |
Proposed issue of securities - NVO
|
26 Feb 2026 9:58AM |
$0.130 |
$0.080 |
fallen by
38.46%
|
|
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$9 |
Proposed issue of securities - NVO
|
26 Feb 2026 9:58AM |
$0.130 |
$0.080 |
fallen by
38.46%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$466 |
Half Year Results Presentation
|
26 Feb 2026 9:58AM |
$11.410 |
$9.250 |
fallen by
18.93%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Maintained underlying profitability with AUD 36.93 million in revenues.
- Profit after tax decreased by 26% to AUD 10.44 million.
- Focus on long-term safety with melanocortins and injectable peptides.
- Ongoing Phase III studies for vitiligo.
- Strategic preparation for U.S. vitiligo market expansion.
- Strong cash reserves of AUD 233 million for self-financing expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$9 |
Commitment Received for A$8.2m Placement
|
26 Feb 2026 9:58AM |
$0.130 |
$0.080 |
fallen by
38.46%
|
|
NVO - Price-sensitive ASX Announcement
Full Release
Key Points
- Firm commitments for A$8.2 million placement received.
- Placement conducted in two tranches; shareholder approval required for Tranche 2.
- Funds to support drilling and exploration in Western Australia.
- Northern Star Ltd. and a director to participate in Tranche 2.
- Options to be offered to CDI Placement participants, subject to approval.
- Planned drilling programs to focus on Wyloo, Balla Balla, and Teichman projects.
- Novo to resume ASX trading with settlement of Tranche 1 on 3 March 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thrive Tribe Technologies Limited (1TT) ORDINARY FULLY PAID |
Information Technology |
$2 |
Notification regarding unquoted securities - 1TT
|
26 Feb 2026 9:57AM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| Cettire Limited (CTT) ORDINARY FULLY PAID |
Consumer Discretionary |
$86 |
H1 FY26 Results Presentation
|
26 Feb 2026 9:57AM |
$0.450 |
$0.225 |
fallen by
50%
|
|
CTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Ex-USA sales revenue growth of 13%, highlighting market share gains.
- Disciplined marketing investments have reduced the rate of new customer acquisitions.
- Strong engagement with repeat customers, accounting for 69% of gross revenue.
- Adjusted EBITDA of $8.7 million, indicating a significant profitability turnaround.
- Cash balance of $61 million with no financial debt, showcasing financial resilience.
- Emerging Markets now make up 45% of gross revenues.
- Localization efforts included launching an Arabic platform for Middle East expansion.
- The luxury goods market is facing a decline, impacting demand, particularly in the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Estrella Resources Limited (ESR) ORDINARY FULLY PAID |
Materials |
$69 |
Ira Miri sample exceeds expectations ahead of completion
|
26 Feb 2026 9:56AM |
$0.032 |
$0.031 |
fallen by
3.13%
|
|
ESR - Price-sensitive ASX Announcement
Full Release
Key Points
- Approximately 22,600 tonnes of manganese extracted.
- Extraction forms part of a 30,000-tonne market sample.
- High-grade ore extracted ahead of sale and shipment.
- Potential for significant project expansion identified.
- Port stockpile location approved by ANM.
- Successful extraction supports a Category A Mining Licence application.
- High workforce engagement and no lost-time injuries.
- Strong support from the Timor-Leste Government.
- Ore ready for international partner assessment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cettire Limited (CTT) ORDINARY FULLY PAID |
Consumer Discretionary |
$86 |
H1 FY26 Results ASX Announcement
|
26 Feb 2026 9:55AM |
$0.450 |
$0.225 |
fallen by
50%
|
|
CTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Cettire reported H1 FY26 gross revenue of $505.7 million.
- Adjusted EBITDA for H1 FY26 was $8.7 million, marking a $20.5 million turnaround from H2 FY25.
- Sales in the US were significantly impacted by new trade policies, particularly the removal of the de minimis exemption.
- Revenue from regions outside the US grew by 13% year-on-year.
- The average order value increased by 17% due to higher US pricing.
- Reduction in marketing expenses by 42% led to a 12% decline in active customers.
- Repeat customers contributed to 69% of gross revenue.
- Emerging markets increased their share of gross revenue to 45%.
- Cettire launched an Arabic language capability and a flagship store on JD.com.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$466 |
CLINUVEL Record Revenues, Advances Strategic Expansion
|
26 Feb 2026 9:55AM |
$11.410 |
$9.250 |
fallen by
18.93%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenues with a 4% increase in sales for the December half-year.
- Twentieth consecutive half-year profit.
- Expenses increased by 22%, impacting net profit after tax by 26%.
- Cash reserves increased to $233 million.
- Strategic focus on low-risk, non-dilutive growth.
- Preparing for expansion in vitiligo and NEURACTHEL® market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mont Royal Resources Limited (MRZ) ORDINARY FULLY PAID |
Materials |
$35 |
Mont Royal Receives Extension of Conditional Funding
|
26 Feb 2026 9:54AM |
$0.205 |
$0.185 |
fallen by
9.76%
|
|
MRZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Extension of conditional funding from Natural Resources Canada (NRCan) for Mont Royal's Ashram Project.
- Funding amounting to up to C$2.6 million from the Critical Minerals Infrastructure Fund.
- Development of Southern Road Access Strategy for enhanced logistics and transportation.
- The infrastructure supports Indigenous communities and other projects in Nunavik.
- The project involves a logistics chain from Ashram to Schefferville and further by rail and sea.
- Ashram Project contains one of the highest quality rare earth and fluorspar deposits globally.
- Conditional funding supports planning, baseline studies, pre-feasibility, and feasibility studies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$466 |
Appendix 4D and Half Year Report
|
26 Feb 2026 9:54AM |
$11.410 |
$9.250 |
fallen by
18.93%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- 10th consecutive half-year profit with strong NPBT and NPAT margins.
- Net assets increased by 3.4% over the past six months.
- Maintained a debt-free position for 21 consecutive years.
- Total revenues decreased by 6% to $40.56 million due to foreign exchange impacts.
- Expansion of the VALLAURIX RD&I Centre in Singapore.
- Advancement in clinical trials for SCENESSE® for treatments like vitiligo and porphyrias.
- Development of NEURACTHEL® for CNS disorders.
- Focus on PhotoCosmetics and controlled-release peptide formulations.
- Prioritization of long-term value creation and strategic capital allocation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Farm Pride Foods Limited (FRM) ORDINARY FULLY PAID |
Consumer Staple |
$50 |
Appendix 4D and Half Year Financial Report
|
26 Feb 2026 9:54AM |
$0.240 |
$0.215 |
fallen by
10.42%
|
|
FRM - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax for the period was $8.295 million.
- Revenue increased by 40.27% to $63.314 million.
- The company completed projects aimed at improving farm and processing efficiency.
- No dividends were declared for the period.
- Net assets increased to $51.294 million.
- Compliance with all debt covenants was maintained.
- Investments include a new standalone rearing farm in Victoria.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,594 |
Pause in Trading
|
26 Feb 2026 9:53AM |
$12.710 |
$12.600 |
fallen by
0.87%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren Pharmaceuticals Limited is listed with the security code NEU.
- A trading pause was announced for Neuren Pharmaceuticals Limited's securities.
- Further announcements from the company are anticipated.
- The announcement was made in compliance with ASX listings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| The Star Entertainment Group Limited (SGR) ORDINARY FULLY PAID |
Consumer Discretionary |
$730 |
Refinancing term sheet with WhiteHawk Capital
|
26 Feb 2026 9:52AM |
$0.125 |
$0.110 |
fallen by
12%
|
|
SGR - Price-sensitive ASX Announcement
Full Release
Key Points
- The Star Entertainment Group Limited (SGR) has executed a refinancing term sheet with WhiteHawk Capital Partners.
- The refinancing proposal aims to address The Star's existing debt and provide additional liquidity for its turnaround plan.
- The executed term sheet is non-binding and the parties aim for a binding commitment by the end of March 2026 and complete the refinancing by mid-May.
- Covenant waivers are being negotiated with existing lenders for the December period to facilitate the refinancing.
- Completion of the refinancing is not dependent on the AUSTRAC case determination.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Unity Office Property Fund (AOF) ORDINARY UNITS FULLY PAID |
Real Estate |
$59 |
HY26 Financial Results
|
26 Feb 2026 9:51AM |
$0.375 |
$0.360 |
fallen by
4%
|
|
| Thrive Tribe Technologies Limited (1TT) ORDINARY FULLY PAID |
Information Technology |
$2 |
Application for quotation of securities - 1TT
|
26 Feb 2026 9:51AM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$132 |
Stronger H1 FY2026 Performance Upward Revision to Guidance
|
26 Feb 2026 9:50AM |
$0.052 |
$0.058 |
risen by
11.54%
|
|
BXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Upgraded FY26 adjusted EBITDA guidance to $16.5 million – $19.0 million.
- H1 FY26 adjusted EBITDA was $8.3 million, up from $3.7 million in the prior period.
- FY26 revenue guidance remains $65 million – $75 million.
- Bioxyne focuses on innovative medicines and psychedelic compounds through its subsidiary.
- CEO Sam Watson highlights margin improvements and efficiency in scaling operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harvest Technology Group Ltd (HTG) ORDINARY FULLY PAID |
Information Technology |
$14 |
Proposed issue of securities - HTG
|
26 Feb 2026 9:49AM |
$0.016 |
$0.012 |
fallen by
25%
|
|
Call 1300 880 160
Start a chat
Schedule a call
